Beijing Tropical Medicine Research Institute, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory for Research on Prevention and Treatment of Tropical Disease, No. 95 Yong-an Road, Xicheng District, Beijing 100050, China.
Biomed Pharmacother. 2022 Jan;145:112366. doi: 10.1016/j.biopha.2021.112366. Epub 2021 Nov 11.
Mycoplasma pneumoniae is a leading cause of community-acquired respiratory infections. Infantile Feire Kechuan Oral Solution (IFKOS) is effective for treatment of M. pneumoniae infection. The aim of this study was to explore the potential mechanism of IFKOS against M. pneumoniae infection in basal epithelial human lung adenocarcinoma A549 cells.
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to determine the effects of IFKOS on the viability of A549 cells infected with M. pneumoniae. Optical microscopy was used to observe cell morphology and a Muse cell analyzer was used to assess apoptosis and the cell cycle phase. Enzyme-linked immunosorbent assays were employed to assess the expression levels of interleukin (IL)-4, IL-6, IL-8, IL-17, tumor necrosis factor (TNF)-α, interferon (IFN)-α, and IFN-γ.
Under certain conditions, M. pneumoniae infection reduced the viability and inhibited the proliferation of A549 cells, promoted early apoptosis, and arrested cells in the G0/G1 phase, thus shortening the S and G2/M phases (all p < 0.05). M. pneumoniae also upregulated expression of IL-8 and TNF-α and downregulated that of IL-6 (p < 0.05), which switched the immune balance of Th1/Th2 to Th1 cells. IFKOS (5.531 mg/mL) improved the viability and proliferation of M. pneumoniae-infected A549 cells, mitigated early apoptosis, and reversed cell cycle arrest in the G0/G1 phase, thereby extending the S and G2/M phases (all, p < 0.05). IFKOS downregulated expression of IL-8 and TNF-α and upregulated that of IL-6 (p < 0.01), thereby reversing the immune imbalance of Th1/Th2. Secretion of IL-4, IL-17, IFN-α, and IFN-γ was not observed.
IFKOS played a protective role in the regulation of cell viability, apoptosis, the cell cycle, and Th1/Th2 immune imbalance induced by M. pneumoniae infection and conveyed an anti-inflammatory effect in A549 cells.
肺炎支原体是社区获得性呼吸道感染的主要原因。小儿肺热咳喘口服液(IFKOS)对肺炎支原体感染的治疗有效。本研究旨在探讨 IFKOS 对人肺腺癌细胞 A549 感染肺炎支原体的潜在作用机制。
用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)法测定 IFKOS 对肺炎支原体感染 A549 细胞活力的影响。光学显微镜观察细胞形态,Muse 细胞分析仪评估细胞凋亡和细胞周期。酶联免疫吸附试验(ELISA)检测白细胞介素(IL)-4、IL-6、IL-8、IL-17、肿瘤坏死因子(TNF)-α、干扰素(IFN)-α和 IFN-γ的表达水平。
在一定条件下,肺炎支原体感染降低 A549 细胞活力,抑制其增殖,促进早期凋亡,使细胞停滞于 G0/G1 期,从而缩短 S 和 G2/M 期(均 p<0.05)。肺炎支原体还上调了 IL-8 和 TNF-α的表达,下调了 IL-6 的表达(p<0.05),从而使 Th1/Th2 免疫平衡向 Th1 细胞转换。IFKOS(5.531mg/mL)可提高肺炎支原体感染 A549 细胞活力和增殖,减轻早期凋亡,逆转 G0/G1 期细胞周期阻滞,从而延长 S 和 G2/M 期(均 p<0.05)。IFKOS 下调了 IL-8 和 TNF-α的表达,上调了 IL-6 的表达(p<0.01),从而逆转 Th1/Th2 免疫失衡。未观察到 IL-4、IL-17、IFN-α和 IFN-γ的分泌。
IFKOS 在调节肺炎支原体感染诱导的细胞活力、凋亡、细胞周期和 Th1/Th2 免疫失衡方面发挥保护作用,并在 A549 细胞中发挥抗炎作用。